In one study, NRAS mutations were detected in 43% of melanoma patients on treatment not present at baseline, receiving vemurafenib, dabrafenib or dabrafenib plus trametinib, before clinical and radiological progression, in their plasma ctDNA samples, suggesting the potential of ctDNA as an early predictor of resistance mechanisms [42]. This evidence concerns the gene NRAS and melanoma.